The QualityStocks Daily Monday, November 20th, 2023

Today's Top 3 Investment Newsletters

Broad Street(BRSH) $0.2950 +74.56%

Schaeffer's(YPF) $15.0100 +39.89%

MarketClub Analysis(STAL) $0.0086 +39.19%

The QualityStocks Daily Stock List

4Cable TV International (CATV)

MarketClub Analysis and QualityStocks reported earlier on 4Cable TV International (CATV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

4Cable TV International, Inc. (OTC: CATV) is a manufacturer of outdoor transmission equipment for the broadband and cable industry through its subsidiary. It operates as a fully integrated CBD/hemp business.

The company, which has its headquarters in Port St. Lucie, Florida, was incorporated in 2007, on November 8th by Andrew F. Staniak and Steven K. Richey. It serves consumers in the United States. It generates most of its revenue from the United States, with a smaller portion coming from Europe. Additionally, it sells and markets its products via a network of dealers in Canada and the United States, mainly to multiple system operators and independent cable TV operators.

The firm provides testing, upgrading and repair, as well as amps, return lasers, line extenders, bridgers, trunk amplifiers and radio frequency. Its product portfolio includes the PowerMiser, SOLAR-CATV, RFoG, RF2F cable, Node+0 and the DSR (Dynamically Scalable Return). Its SOLAR-CATV product uses solar power to help operators extend their services to rural areas while its DSR technology permits nodes to adjust their return bandwidth. The firm also operates and owns research and manufacturing facilities in Conway, South Carolina.

The enterprise’s patent-pending innovations provide cable TV, digital, phone and broadband service providers with cost-effective solutions which save energy, extend system penetration and maximize bandwidth.

The firm recently concluded the acquisition of a CIGN LLC, which grows hemp flower and seedlings. This move furthers its strategy to become a fully integrated global CBD/hemp business. The acquisition will also allow the firm to operate a state of the art Cravo Grow facility, which will increase the firm’s revenues, thus attracting more investments into the firm.

4Cable TV International (CATV), closed Monday's trading session at $0.0035, up 45.8333%, on 64,834,383 volume. The average volume for the last 3 months is 34,710 and the stock's 52-week low/high is $0.0001/$0.0039.

Xiaomi Corp. (XIACF)

MarketBeat, Trades Of The Day, MarketClub Analysis, TradersPro, Daily Trade Alert, StreetInsider and InvestorPlace reported earlier on Xiaomi Corp. (XIACF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Xiaomi Corp. (OTC: XIACF) (HKG: 1810) (FRA: 3CP) (BMV: 1810N) is an investment holding firm engaged in the provision of hardware and software services.

The firm has its headquarters in Beijing, China and was incorporated in 2010, on March 3rd by Jiang Ji Huang, Chuan Wang, De Liu Feng Hong, Wan Qiang Li, Bin Lin and Jun Lei. It operates as part of the consumer electronics industry, under the technology sector. The firm serves consumers in Mainland China and globally.

The enterprise operates through Smartphones, Internet Services, IoT and Lifestyle Products, and Others segments. The Smartphones segment sells smartphones while the Internet Services segment offers advertising services and internet value-added services; and engages in the online game and fintech businesses. The IoT and Lifestyle Products segment provides smart TVs, laptops, AI speakers, and smart routers; a range of IoT and other smart hardware products; and lifestyle products. On the other hand, the Others segment provides hardware repair services for its products; and installation services for certain IoT products. The enterprise also engages in the development and sale of software, hardware, and television; wholesale and retail of smartphones and ecosystem partners' products; operation of retail stores;procurement and sale of smartphones, ecosystem partners' products, and spare parts; and procurement of raw materials. In addition to this, it is also involved in commercial factoring activities; the provision of advertising and promotion services; e-commerce business; electronic payment technology services; sale of e-books; technical services; and integrated circuit chip design services.

The company, in partnership with Ambiq, recently launched the Xiaomi Smart Band 8, a new smart band to assist consumers in defining their unique style. This move opens it up to new growth and investment opportunities while also creating new avenues for value creation.

Xiaomi Corp. (XIACF), closed Monday's trading session at $2.091, up 0.722543%, on 29,002 volume. The average volume for the last 3 months is 3,076 and the stock's 52-week low/high is $1.18/$2.20.


We reported earlier on TECO 2030 (TECFF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

TECO 2030 ASA (OTCQX: TECFF) (FRA: TE9) is an engineering and equipment development firm for the maritime industry.

The firm has its headquarters in Lysaker, Norway and was incorporated in 2019, on September 30th. It operates as part of the specialty industrial machinery industry, under the industrials sector. The firm serves consumers in Asia, the United States, Europe and South America.

The company is developing hydrogen fuel cells that enable ships and other heavy-duty applications to become emissions-free. It operates through the Hydrogen Fuel Cell and Future Funnel segments. The Hydrogen Fuel Cell segment is involved in converting hydrogen into electricity while emitting nothing but water vapor and warm air that is designed for use in heavy-duty and marine applications. On the other hand, the Future Funnel segment provides exhaust gas cleaning systems which help to reduce harmful pollution from ships.

The enterprise’sofferings include TECO Future Funnel; TECO Marine Fuel Cell, a modular hydrogen proton exchange membrane fuel cell system primarily designed for heavy-duty marine applications; TECO - AVL EPOS, a condition monitoring and automatic diagnostic using expert algorithms; andTECO Ballast Water Treatment System, which is used to prevent invasive species and health issues. It also offers carbon capture and storage solutions.

The company recently signed a supply agreement with Pherousa Green to realize ammonia powered zero-emission deep-sea shipping for 6 modern, zero-emission Ultramax dry bulk carriers. This move may help extend the company’s consumer reach, open it up to new growth and investment opportunities and greatly bolster its overall growth.

TECO 2030 (TECFF), closed Monday's trading session at $0.44, even for the day. The average volume for the last 3 months is 77,945 and the stock's 52-week low/high is $0.44/$1.38.

Minaurum Gold (MMRGF)

We reported earlier on Minaurum Gold (MMRGF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Minaurum Gold Inc. (OTCQX: MMRGF) (CVE: MGG) (FRA: 78M) is an exploration stage firm focused on acquiring and exploring for mineral properties.

The firm has its headquarters in Vancouver, Canada and was incorporated in 2007, on November 13th. Prior to its name change in November 2009, the firm was known as Chava Resources Limited. It operates as part of the gold industry, under the basic materials sector. The firm serves consumers in Mexico and the United States.

The company primarily explores for gold, silver, copper, lead, and zinc deposits. Through a project portfolio containing approximately 76,717 hectares, it provides significant exposure to precious and base metals.

The enterprise’s flagship project is the Alamos project, which covers an area of approximately 37,928 hectares in Southern Sonora. It is located in the historic Alamos silver mining district, located adjacent to the Aurifero gold project, and further south, the jointly ventured Adelita copper-silver project in Sonora. Its other projects include the Santa Marta VMS gold-copper project, Aurena gold project and Taviche silver-gold project, all located in Oaxaca. The Vuelcos del Destino and Biricu gold projects are surrounded by gold-producing mining companies in the heart of the Guerrero Gold Belt.

The firm recently appointed a new member to its board of directors, who has decades of mining and exploration experience as well as experience in management, having spent over a decade holding a number of top managerial positions. This move may positively influence the firm’s performance while also allowing it to apply his technical expertise to the firm’s exploration efforts in Mexico.

Minaurum Gold (MMRGF), closed Monday's trading session at $0.1386, off by 1.2117%, on 65,508 volume. The average volume for the last 3 months is 2,817 and the stock's 52-week low/high is $0.0797/$0.21.

Aben Minerals (ABNAF)

QualityStocks, InvestorIntel and AllPennyStocks reported earlier on Aben Minerals (ABNAF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Aben Minerals Ltd (OTC: ABNAF) (CVE: ABM) (FRA: R26) is an exploration and development-stage firm focused on acquiring and exploring for mineral properties.

The firm has its headquarters in Vancouver, Canada and was incorporated in 1960, on February 8th. Prior to its name change in February 2023, the firm was known as Aben Resources Limited. It operates as part of the gold industry, under the basic materials sector. The firm primarily serves consumers in British Columbia, Yukon and Saskatchewan, Canada.

The company primarily explores for gold and graphite deposits. Its flagship project is the Forrest Kerr Gold project, which covers an area of 23,397 hectares and is located in the heart of British Columbia’s Golden Triangle in northwestern British Columbia, Canada. Its other projects include the Slocan Graphite Project, which covers over 2,826 hectares and is located in the Valhalla Range of the southern Selkirk Mountains, roughly 28km north of the city of Castlegar and 30km west of the city of Nelson, in southeast British Columbia. It also owns interests in the Pringle North property, which comprises of 5 contiguous mining claims that cover approximately 1,881 ha. The company’s Justin Gold Project is 35km southeast of the Cantung Mine and holds approximately 7,400 ha of land.

The enterprise, which recently concluded a camp reclamation and preparation program at its Justin Gold Project in the Yukon, remains focused on advancing exploration efforts at its properties with a focus on acquiring a new exploration permit to allow for advanced exploration at the Justin project, and creating additional value for its shareholders.

Aben Minerals (ABNAF), closed Monday's trading session at $0.055, up 3.0986%, on 5,100 volume. The average volume for the last 3 months is 13,285 and the stock's 52-week low/high is $0.05/$0.31.

Noble Roman’s (NROM)

QualityStocks, TaglichBrothers, MarketBeat, Wall Street Resources, The Bowser Report,, FeedBlitz, TopPennyStockMovers, StockOodles and SmallCapVoice reported earlier on Noble Roman’s (NROM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Noble Roman's, Inc. (OTCQB: NROM) is a restaurant operator that is focused on selling and servicing franchises, as well as licensing and operating foodservice locations for stand-alone restaurants and non-traditional foodservice operations.

The firm has its headquarters in Indianapolis, Indiana and was incorporated in 1972. It operates as part of the restaurants industry, under the consumer cyclical sector. The firm mainly serves consumers in the United States.

The company operates stand-alone restaurants and non-traditional foodservice operations under the trade names Noble Roman's Pizza, Noble Roman's Craft Pizza & Pub, Tuscano's Italian Style Subs and Noble Roman's Take-N-Bake. The Noble Roman's Craft Pizza & Pub offers a selection of over 40 different toppings, sauces and cheeses from which to choose. Beer and wine are also featured, with 16 different beers on tap, including both national and local craft selections. Its beer and wine service is provided at the bar and throughout the dining room. The company owns and operates approximately nine Craft Pizza & Pub locations and one non-traditional location in a hospital. Craft Pizza & Pub is designed to have a fun, pleasant atmosphere serving pizza and other related menu items. The company's subsidiaries include Pizzaco Inc. and RH Roanoke Inc.

The enterprise recently announced its latest financial data, with continuous growth in the non-traditional franchising segment being the largest contributor to the improvement in its results. It remains focused on investing in its growth, appealing to new consumers and expanding non-traditional franchising efforts. This may, in turn, help create additional value for its shareholders.

Noble Roman’s (NROM), closed Monday's trading session at $0.39, even for the day. The average volume for the last 3 months is 56,426 and the stock's 52-week low/high is $0.1831/$0.435.

HNR Acquisition Corp. (HNRA)

We reported earlier on HNR Acquisition Corp. (HNRA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

HNR Acquisition (NYSE American: HNRA), a special purpose acquisition company prior to today, has completed its business combination with Pogo Resources LLC and Pogo subsidiaries. According to the announcement, HNRA has completed its business combination through acquisition of all equity interests in Pogo Resources LLC and its subsidiaries, including interests in the Grayburg-Jackson oil field in the prolific Permian Basin in Eddy County, New Mexico. The company noted that the Northwest Shelf contains the largest recoverable reserves among all the unconventional basins in the United States, and Pogo's holdings include 13,700 contiguous leasehold acres, 343 producing wells and 207 injection wells for a total of 550 wells. HNRA management worked hard to identify the right combination, and “Pogo Resources LLC fit all of our criteria for revenues, earnings,” a company official stated. “We believe that there is a significant upside to grow the company and expand the revenues and profits.”

The announcement also noted that the company is aggressively looking to acquire working interests in substantial resources in the Permian Basin in an effort to expand the Grayburg-Jackson Field by focusing on acquisitions that complement the company’s current footprint in the Permian Basin. “In all the years I have worked in the petroleum industry, I have never seen such upside potential in one field as I see in the Grayburg-Jackson Field,” said HNRA CEO Dean Rojas in the press release. “Not only do I believe we will be increasing production by at least two and a half times to approximately 4,000 barrels a day in 36 months, but there is potential at deeper levels in the field. Our research indicates that the stacked-play potential of the Northwest Shelf of the Permian Basin, combined with favorable drilling economics, supports our findings that by continuing to improve our leasehold position, well-spacing and completions, we will recover a greater portion of oil from the reserves. In addition, we have a superior management and operating team with many years of experience in the petroleum industry.”

To view the full press release, visit

About HNR Acquisition Corp.

HNRA was a blank check company, otherwise known as a special purpose acquisition company, or SPAC, before today. The company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. HNRA's stock will continue to trade on the NYSE American Stock Exchange. For more information on the company, visit

HNR Acquisition Corp. (HNRA), closed Monday's trading session at $1.56, off by 18.75%, on 483,706 volume. The average volume for the last 3 months is 818,323 and the stock's 52-week low/high is $1.42/$13.93.

Curaleaf Holdings Inc. (CURLF)

InvestorPlace, Kiplinger Today, MarketBeat, QualityStocks, Cabot Wealth, Daily Trade Alert, Top Pros' Top Picks, MarketClub Analysis, Profit Trends, The Online Investor, StreetInsider, Wealth Insider Alert, Early Bird, Trades Of The Day, Trading For Keeps, The Street, Investment U, Daily Profit, CFN Media Group, StreetAuthority Daily, Zacks, TradersPro, Wyatt Investment Research, wyatt research newsletter and Schaeffer's reported earlier on Curaleaf Holdings Inc. (CURLF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A recent survey indicates a growing optimism among institutional investors towards U.S. marijuana multistate operators (MSOs). Conducted by Calgary-based ATB Capital Markets, the survey involved 23 institutional investors, primarily hedge funds.

Frederico Gomes, the lead author of the report and a marijuana equity analyst, highlighted the increased bullish sentiment among investors, driven primarily by the potential rescheduling of marijuana by the federal government. The survey reveals that about 61% of respondents believe U.S. marijuana MSOs will outperform the S&P 500 in the next year. However, despite this positive sentiment, Gomes notes that the capital influx has not yet aligned with the bullish outlook from an institutional perspective.

The likelihood of the U.S. government rescheduling cannabis from Schedule 1 to 3 within the next 18 months was perceived as 75% by the surveyed investors. Yet, the majority of them reported either no change or reduced exposure to MSOs in the past six months. This indicates a cautious approach, possibly due to past regulatory uncertainties.

Investors expressed a 50% probability of Congress passing the SAFER Banking Act, legislation facilitating financial institutions to serve state-legal marijuana businesses without federal repercussions. This uncertainty is attributed to past failures in marijuana banking reform legislation and political ambiguities surrounding the new GOP speaker of the U.S. House of Representatives, Mike Johnson.

ATB sought to understand the factors influencing investors’ willingness to invest more in MSOs. Cannabis rescheduling emerged as the top priority for nearly 61% of respondents. On the other hand, the possibility of more MSO stock listings on the Toronto Stock Exchange (TSE) was deemed to be the least significant element.

Regarding capital allocation preferences, investors indicated a preference for MSOs to prioritize deleveraging and debt repayment, with organic growth being the second-most desired behavior. Mergers and acquisitions were not favored, and share repurchases ranked as the least-desired way for MSOs to allocate capital.

While investors displayed increased bullishness towards U.S. MSOs, their outlook on Canadian licensed retailers and producers was less optimistic, with 60% expecting underperformance compared to the S&P 500. The negative sentiment in Canada is attributed to poor operating results and shareholder dilution.

Interestingly, the survey revealed that only 52% of investors expressed interest in Canadian marijuana retailers and producers. This disparity can point to a possible acquisition opportunity for investors who are not conventional thinkers in the Canadian marijuana market.

Gomes noted that investors are wary due to past setbacks and are waiting for signs of improvement in terms of profitability and sustainable operations. The report notes that achieving sustainable profitability and positive free cash flow is seen as the most crucial factor, followed by a reduction in excise taxes.

As the policy direction of the United States becomes more clear after the U.S. Drug Enforcement Administration releases its rulemaking recommendation, cannabis companies such as Curaleaf Holdings Inc. (CSE: CURA) (OTCQX: CURLF) may attract more investor interest.

Curaleaf Holdings Inc. (CURLF), closed Monday's trading session at $3.49, off by 3.8567%, on 309,184 volume. The average volume for the last 3 months is 43.226M and the stock's 52-week low/high is $2.19/$7.90.

NIO Inc. (NIO)

Green Car Stocks, InvestorPlace, Schaeffer's, MarketClub Analysis, The Street, MarketBeat, StocksEarning, Daily Trade Alert, Trades Of The Day, Kiplinger Today, The Online Investor, QualityStocks, StockEarnings, INO Market Report, Zacks, Early Bird, StreetInsider, StockMarketWatch, BUYINS.NET, Cabot Wealth, Wealth Insider Alert, GreenCarStocks, InvestorsUnderground, FreeRealTime, Money Wealth Matters, The Wealth Report, TipRanks, CNBC Breaking News, Daily Wealth, wyatt research newsletter, TradersPro, Investopedia, Energy and Capital, CRWEWallStreet, Green Energy Stocks, InvestorIntel, Investors Alley, InvestorsObserver Team, MarketClub, Louis Navellier, TopPennyStockMovers, AllPennyStocks, Wealth Daily, Smartmoneytrading, Stock Market Watch, The Night Owl, Top Pros' Top Picks, Top Pros’ Top Picks and Jim Cramer reported earlier on NIO Inc. (NIO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Oil giant Exxon Mobil has announced the acquisition of a drill operation in Arkansas that will expand its efforts to enter the lithium production side of the electric vehicle supply chain. The oil and gas company plans on producing lithium, a mineral critical to the development of electric vehicle batteries as soon as 2027.

Exxon Mobil decided to venture into the electric-vehicle battery-metal production segment. The company started by purchasing a whopping 120,000 acres of Smackover Formation, a geological site located in southern Arkansas with rich lithium deposits. It now plans on launching a drilling operation on the massive site that would see it become one of the globe’s leading lithium producers.

The company will begin producing lithium at Smackover Formation within the next four years and hopes to start supplying enough lithium to support the manufacture of a million EVs per year by 2030. According to a statement from Exxon, the oil and gas drilling giant is currently holding discussions with potential customers in the EV and battery manufacturing segments.

Like most companies in the fossil-fuel production industry, Exxon Mobil will have to pivot to a more environmentally sustainable business model as the globe transitions from fossil fuels to cleaner alternatives. Experts predict that the global demand for oil, coal and gas will peak by 2030, meaning fossil fuel companies have limited time to figure out a way forward.

While Exxon is turning to lithium, a critical EV battery metal that’s expected to run into supply issues in a few years, major oil companies such as BP and Shell are instead focusing on renewables, including solar and wind. Exxon will also invest $1.7 billion through 2027 in the reduction of greenhouse gas emissions with a focus on biofuels, hydrogen and carbon capture.

Exxon’s president of low carbon solutions Dan Ammann says increasing local lithium production will be critical to the energy-transition movement. Lithium is a decades-long investment with significant potential for growth, Ammann said, especially now that the United States is actively transitioning toward electric cars.

The Biden administration has provided billions of dollars to help build out the country’s network of public charging infrastructure as well as thousands of dollars in subsidies and tax incentives for electric vehicle purchases. However, even though the country has one of the largest lithium deposits on the globe, it is heavily reliant on nations such as Chile and Argentina for lithium imports.

Heavy investment into building up local production would limit the nation’s reliance on imports, fortify the supply chain against outside factors and ensure a steady supply of lithium for the nation’s growing fleet of electric cars. As lithium and other needed raw materials increase in supply, automakers such as NIO Inc. (NYSE: NIO) could see their production costs dropping. In turn, they can pass those cost savings to their customers. This could accelerate EV adoption in the long-term.

NIO Inc. (NIO), closed Monday's trading session at $7.8, up 5.548%, on 62,067,268 volume. The average volume for the last 3 months is 5.409M and the stock's 52-week low/high is $7.00/$16.18.

Seelos Therapeutics Inc. (SEEL)

QualityStocks, MarketBeat, StockEarnings, StockMarketWatch, MarketClub Analysis, TradersPro, Schaeffer's, BUYINS.NET, Trades Of The Day, Prism MarketView and INO Market Report reported earlier on Seelos Therapeutics Inc. (SEEL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Many experts believe psychedelic-assisted therapy represents a new frontier in psychiatric treatments. A growing body of scientific literature has connected various psychedelics with significant and long-term improvements in mental health with barely any side effects. Consequently, plenty of experts in the scientific and medical communities now consider psychedelics as potential treatments for debilitating mental conditions such as post-traumatic stress disorder (PTSD), treatment-resistant depression and eating disorders.

But with psychedelic research still in its infancy, scientists are studying hallucinogens such as psilocybin, LSD and ayahuasca diligently and making discoveries regularly. Recent research efforts have found that hallucinogens may also be able to help trans people deal with mental-health challenges.

While scientists don’t fully understand the mechanisms behind psychedelics, we know that they can induce profound realizations and help people change how they perceive themselves and the world around them. For Mikayla, a trans woman who had dealt with gender dysphoria and suicidal thoughts since early puberty, this aspect of the psychedelic experience changed her life. Although a few of the studies she read online explored using psychedelic conversion therapies to “cure” trans people, Mikayla’s experience with psychedelics was wildly different.

She took psilocybin mushrooms and was filled with the realization that there was nothing inherently wrong with her. Rather than relieve her of the “burden” of being trans, the psychedelic helped her finally start to love herself as she was and begin the process of shedding a lifetime of self-hatred.

Most psychedelic research efforts have focused on more common conditions such as depression, anxiety and PTSD, but hallucinogens may also have applications for trans people dealing with various mental issues. Research shows that psychedelic therapy is especially effective when combined with guided talk therapy because it provides patients with the help they need to make sense of their psychedelic experiences and integrate any realizations they had during the experience into their lives.

Members of the transgender community tend to suffer from mental-health conditions such as anxiety, depression and suicidal thoughts, often from a young age. However, this community is severely underrepresented in clinical trials, especially ones with the potential to offer significant relief, such as psychedelic-related clinical trials. These trials often have long wait lists of prospective enrollees and strict criteria that exclude a majority of hopefuls.

Since clinical studies are essentially the only legal way to access psychedelic treatments (except ketamine) in the United States, many trans individuals such as Mikayla have to act outside the medical system to get the relief they desperately need.

Enterprises such as Seelos Therapeutics Inc. (NASDAQ: SEEL) are doubling down on their efforts to advance their psychedelic drug pipelines so that different categories of patients can benefit from these revolutionary treatments.

Seelos Therapeutics Inc. (SEEL), closed Monday's trading session at $0.1239, off by 2.0553%, on 3,136,194 volume. The average volume for the last 3 months is 33.289M and the stock's 52-week low/high is $0.1065/$1.66.

Marathon Digital Holdings Inc. (MARA)

MarketClub Analysis, InvestorPlace, Schaeffer's, QualityStocks, INO Market Report, StockMarketWatch, MarketBeat, StocksEarning, StockEarnings, TradersPro, BUYINS.NET, The Online Investor,, Trades Of The Day, Zacks,, InvestorsUnderground, Early Bird, Daily Trade Alert, The Street, TraderPower, BillionDollarClub, PoliticsAndMyPortfolio, TopPennyStockMovers, Wall Street Mover, StreetAuthority Daily, FeedBlitz, Kiplinger Today, Wealth Insider Alert, Eagle Financial Publications, Barchart, DreamTeamNetwork, Promotion Stock Secrets, AllPennyStocks, Rick Saddler, Stock Analyzer, Stock Beast, StockOodles, Street Insider, StreetInsider and RedChip reported earlier on Marathon Digital Holdings Inc. (MARA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The United Kingdom recently made a significant stride to address the challenge of individuals exploiting crypto-assets to elude and circumvent significant amounts of uncollected tax through a joint declaration with 48 nations. Spearheaded by the UK, the Crypto-Asset Reporting Framework (CARF) stands as the latest tax transparency standard introduced by the OECD. Under this framework, crypto platforms will be mandated to share taxpayer information with tax authorities, a practice currently absent in their operations.

The new framework ensures that tax authorities can collaboratively exchange information, fortifying their ability to enforce tax compliance. The implementation of CARF is anticipated to commence in 2027, facilitating exchanges with partner nations. The initiative builds upon the global tax accord of 2021, encompassing two pillars designed to guarantee that businesses pay the appropriate taxes where they operate. Additionally, it targets significant multinational enterprises engaging in tax avoidance by imposing a 15% global minimum tax rate.

Victoria Atkins, the financial secretary to the Treasury, expressed pride in the UK’s leadership role in addressing global tax evasion, emphasizing the importance of securing revenue essential for public services and conveying a resolute message that leveraging crypto for tax evasion would not be tolerated.

The CARF is positioned to enhance the existing system employed by tax authorities for sharing information, known as the Common Reporting Standard. Launched in 2014, this standard has proven highly successful in combating offshore tax evasion, leading to the recovery of almost $125 billion in additional tax revenue from conventional financial assets.

The newly introduced framework is considered indispensable in confronting the escalating levels of tax avoidance fueled by the rapid expansion of the global crypto market. Estimates suggest that noncompliance with taxes on crypto-asset holdings ranges from 55% to 100%, underscoring the urgency of addressing this issue. Globally, companies are increasingly exploiting cryptocurrency assets to hide profits and evade taxes, contributing to the growing problem of cryptocurrency tax evasion. Companies use methods such as offshore wallets and exchanges or engaging in wash trading to generate fictitious capital losses. Although precise figures are still unknown, estimates place the annual amount in the tens of billions of dollars.

Leveraging its standing as a global leader in tax transparency, the UK plays a pivotal role in shaping, negotiating and finalizing the provisions of CARF. The implementation of this framework is poised to enable the UK to potentially recover hundreds of millions of pounds, reinforcing its commitment to combating tax evasion on an international scale.

This move to streamline the collection and sharing of tax information on an international basis shows enterprises such as Marathon Digital Holdings Inc. (NASDAQ: MARA) that countries are now taking crypto serious and are setting up systems to bring this industry into the mainstream fabric of business life.

Marathon Digital Holdings Inc. (MARA), closed Monday's trading session at $10.64, up 6.4%, on 55,879,613 volume. The average volume for the last 3 months is 2.525M and the stock's 52-week low/high is $3.11/$19.875.

Cronos Group Inc. (CRON)

InvestorPlace, Schaeffer's, Kiplinger Today, MarketClub Analysis, The Street, StocksEarning, MarketBeat, Daily Trade Alert, Trades Of The Day, Wealth Insider Alert, The Online Investor, QualityStocks, Market Intelligence Center Alert, StockMarketWatch, StreetInsider, StockEarnings, BUYINS.NET, Zacks, The Wealth Report, Top Pros' Top Picks, Stock Up Featured, Investopedia, Cabot Wealth, Daily Profit, InvestmentHouse, Early Bird, InsiderTrades, Jim Cramer, The Rich Investor, InvestorsObserver Team, VectorVest, Money Morning, TheTradingReport, 24/7 Trader, Wall Street Window, Small Cap Firm, Stock Gumshoe and InvestorsUnderground reported earlier on Cronos Group Inc. (CRON), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

New research shows that the likelihood of a patient visiting an ER and getting a cannabis use disorder diagnosis is 50% lower in legal cannabis states in comparison to prohibitionist states. The research examined data obtained from emergency departments for the period between 2017–2020. Researchers focused on the states of Oregon and Colorado, which have legalized marijuana, and Rhode Island and Maryland, which still prohibit the use of marijuana.

Specifically, the researchers assessed “treat & release” visiting rates, in which patients received cannabis-use disorder diagnoses that indicated problematic use of the substance. In total, the researchers had to analyze more than 17 million ER visits, which they did using a multivariate logistic regression model.

The researchers revealed that they naturally expected to find higher cannabis-use disorder rates in states that have legalized the drug given that previous studies had found that ending prohibition was linked to slight increases in cannabis use by adults. However, they were surprised when the data indicated that recreational marijuana states had lower odds of cannabis-use disorder in comparison to states where the drug remained illegal.

In their report, the researchers stated that their findings could inform actions of policymakers and recommended that additional studies and analysis of the cannabis use disorder-legalization interrelationship be done in emergency departments, among other healthcare settings. They added that previous studies regarding post-legalization ER visits and hospitalizations had primarily centered on the youth, which meant even slight changes could look more noticeable due to the comparatively low prevalence of marijuana use within said population.

They also noted that in legal states, providers were more tolerant of marijuana use and less likely to recognize problematic behavior associated with cannabis-use disorder, which reduced the chances of proper diagnosis and documentation of cannabis-use disorder in medical records. This, the researchers assume, could account for lower prevalence of the disorder in emergency departments in legal states.

In their report, the researchers also cited separate findings which determined that decreasing admissions for cannabis-use disorder following legalization may have reduced stigma while also increasing the societal acceptability of marijuana use.

The authors published their findings in the “Preventative Medicine Reports” journal.

In other news, findings from a study published by the American Medical Association show that the use of marijuana among the youth has actually been decreasing as more states scrap prohibition laws in favor of regulated recreational sales for eligible individuals. A separate study by NIDA also determined that state-level marijuana legalization was not linked to an increase in use among the youth.

All this scientific data goes to dispel some of the claims made by opponents of cannabis legalization that creating a regulated market in which companies such as Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) are allowed to operate will result in a spike in cannabis use by the youth.

Cronos Group Inc. (CRON), closed Monday's trading session at $2.09, up 6.6327%, on 2,283,445 volume. The average volume for the last 3 months is 80,962 and the stock's 52-week low/high is $1.64/$3.616.

The QualityStocks Company Corner

SenesTech Inc. (NASDAQ: SNES)

The QualityStocks Daily Newsletter would like to spotlight SenesTech Inc. (NASDAQ: SNES).

SenesTech Inc., a visionary leader in fertility control to manage animal pest populations, has developed products that show success in limiting rat populations using unique non-lethal fertility reduction products

Rodents are often associated with carrying diseases that can affect humans, and SenesTech's non-lethal population-reducing technology targets this major problem in a uniquely humane, environmentally conscious, yet effective way

The Arizona-based company has developed two primary products — its liquid ContraPest(R) brand, and the recently introduced Evolve(TM) Soft Bait formulation, soft bait being favored by rodent control professionals

The company anticipates using their technology to develop similar pest-control products for other species in the near future

SenesTech (NASDAQ: SNES), the leader in fertility control to manage animal pest populations, has renewed and expanded its distribution with DIY Pest Control. The expansion includes a stocking order for Evolve(TM) Soft Bait, the first and only soft bait product featuring breakthrough, next-generation technology that targets rodent populations by using nonlethal methods to restrict fertility. A leading online distributor of pest control, DIY Pest Control is a family-owned business that services and supplies pest-control companies and consumers. According to the announcement, SNES's Evolve targets a rat's ability to rapidly reproduce, effectively reducing fertility in rodents in numerous independent studies. "We are extremely pleased to expand our distribution relationship with DIY Pest Control to now include our breakthrough soft bait fertility control solution, Evolve," said SenesTech president and CEO Joel Fruendt in the press release. "For the past two years, DIY has been a key distributor of our ContraPest(R) products. This substantial stocking order for our newest product, Evolve, expands the relationship between the two companies and our joint commitment to providing customers with innovative solutions to address rodent control. As a leader in the pest-management supply business for professionals and consumers, DIY is an ideal partner for SenesTech."

To view the full press release, visit

SenesTech Inc. (NASDAQ: SNES) is the rodent fertility control expert and the inventor of the only EPA-registered contraceptive for male and female rats. The company’s technology provides an innovative and humane method for managing rat populations.

SenesTech is focused on developing effective solutions that are grounded in science and proven through research, all while providing value to people, communities and the environment. The company’s passion is to create a healthier world by better controlling rat pest populations. This aim is critical, as, if left unchecked, a breeding pair of rats and their descendants can produce up to 15,000 pups after just one year.

The company strives for clean cities, efficient businesses and happy households – with a product that was scientifically designed to be effective without killing rats. SenesTech is committed to the sustainable, humane treatment of animals, improving the quality of all human life and enhancing environmental stewardship through the global application of its effective solution in fertility control technology.

SenesTech is headquartered in Phoenix, Arizona.


SenesTech’s first product, ContraPest®, applies revolutionary technology to a global challenge that has persisted since the Middle Ages – the proliferation of rats in urban and agricultural settings. ContraPest® targets the reproductive capabilities of Norway and roof rats. As a highly palatable liquid, the formulation promotes sustained consumption, helping to reduce fertility in both male and female rats, bringing populations down and keeping them down.

The company’s flagship offering can be used as part of integrated pest management (IPM) programs – fitting seamlessly into all IPM programs – to help reduce reproduction and magnify the success of these protocols, or as a standalone solution for customers who want to reduce or eliminate the use of lethal rodent control methods.

In multiple, independent field deployments, ContraPest was shown to reduce rat activity over 90% when added to an existing IPM program.

ContraPest® is registered federally as a General Use Product.

Delivery Systems and New Products

In July 2023, SenesTech began to distribute a new delivery system for ContraPest®, the Isolate Bait System™. This new delivery system brings to market a simple design that enables more efficient deployment, incorporates an enhanced formulation of ContraPest® that is expected to provide improved performance of the fertility control bait in the field and is paired with a new bait station that is more space-efficient and economical.

The other delivery systems available for ContraPest include the Ultimate Bait System™, a tank and tray in a larger format for use with more severe infestations, and the Elevate Bait System™, a unique delivery system that targets above ground infestations, as with roof rats.

SenesTech, as of August 2023, is also in the final stages of releasing a soft bait formulation, which provides the unique attributes of proven fertility control in an industry-familiar format demanded by big box retailers, key e-commerce channels and leading industry pest management professionals.

Market Opportunity

According to SenesTech’s figures, rats cause over $27 billion in damage to public and private infrastructure annually in the United States. Rats also destroy 20% of the global stored food supply every year by consuming or contaminating it.

Rats are known to spread at least 35 diseases, globally posing a dangerous risk to public health and safety. Not only does this age-old problem persist despite extensive campaigns to eradicate it, but multiple sources have reported that post-COVID rat populations have boomed.

Poison-based control methods sicken rats, and they typically die slowly. An animal that eats a poisoned rat may also sicken or die. The global rodenticide market is projected to be worth $1.7 billion by 2026.

In one case study, results reported by the customer showed a $5,000 investment in ContraPest® saved more than $500,000 annually in reduced labor, loss and damage.

Management Team

Joel Fruendt is SenesTech’s President and CEO. He has 15 years of executive leadership in the vector and pest control industries as Vice President and General Manager of Clarke Environmental Inc., a leading vector and pest control products and services company. He has extensive expertise in the development and manufacturing of EPA-registered chemical control products, and the commercialization and sale of those products. He received the ‘Smart Leaders’ award from Smart Business Magazine and holds a bachelor’s degree in business from Illinois Wesleyan University.

Tom Chesterman is CFO at SenesTech. He has over 20 years of experience as the CFO of public companies in the life science, tech and telecommunications industries. Most recently, he was the Vice President and Treasurer of GCI, a telecommunications company. Previous to that, he was the CFO of life science companies Bio-Rad Laboratories, Aradigm and Bionovo. He has a bachelor’s degree from Harvard University and an MBA from the University of California at Davis.

Dan Palasky is Chief Technical Officer at SenesTech. Previously he held the title of Vice President of Research & Development at PLZ Corp., a manufacturer of chemical consumer products, serving as the technical expert for its entire product portfolio. He started his career with Camie-Campbell, Inc., as a chemist in the R&D department. Mr. Palasky received his bachelor’s degree in chemical engineering from the Missouri University of Science & Technology and his MBA in Project Management from Aspen University.

SenesTech Inc. (NASDAQ: SNES), closed Monday's trading session at $2.97, up 26.9231%, on 710,974 volume. The average volume for the last 3 months is 253,640 and the stock's 52-week low/high is $2.10/$80.952.

Recent News

Turbo Energy S.A. (NASDAQ: TURB)

The QualityStocks Daily Newsletter would like to spotlight Turbo Energy S.A. (NASDAQ: TURB).

Turbo Energy in September 2023 announced its successful debut on the Nasdaq stock exchange

The company operates as a subsidiary of Umbrella Solar Investment S.A.

Turbo Energy's total revenue for the year ended December 31, 2022, increased by 82% year-over-year to €31,148,676 (approximately $33,321,219)

In October 2023, the company was awarded a software patent in Spain related to its flagship Sunbox product

Turbo Energy S.A. (NASDAQ: TURB) designs, develops and distributes equipment for the generation, management and storage of photovoltaic energy in Spain, Europe and internationally.

Turbo Energy’s products include lithium-ion batteries and inverters. Additionally, the company recently launched its flagship product, the Sunbox, an all-in-one device that integrates most of the equipment required for a residential photovoltaic installation. The Sunbox is powered by AI and features a software system that monitors the generation, use and management of photovoltaic energy by analyzing large amounts of data related to energy generation, consumption, market prices and weather forecasts. This AI system optimizes battery usage, reducing electricity bills and providing peak-use reduction and uninterruptible power supply functions.

Turbo Energy currently sells its photovoltaic energy equipment primarily through distributors for residential consumers in Spain, but it possesses the expertise and international perspective to expand its product portfolio into industrial and commercial scale and markets, as well as advancing the internationalization process it has already started. The company plans to expand into the industrial photovoltaic sector with its new Sunbox, launched in 2023, in higher power and capacity variants. Its goal is to become a significant player in this sector and contribute to the growth of renewable energy solutions.

The company was incorporated in 2013 and is based in Valencia, Spain. It operates as a subsidiary of Umbrella Solar Investment S.A.


Lithium-Ion Batteries

Turbo Energy is one of the leading companies that introduced lithium-ion batteries for photovoltaic energy storage in Spain. Primarily for the home energy storage market, the company’s batteries have capacities from 2.24 kWh to 5.1 kWh in 24 and 48 volts. In addition, its 48V / 5.1 kWh units are available in a dual battery system.


The inverter converts the direct current produced by the photovoltaic panels into alternating current that can be used by household appliances. It also regulates battery charging and discharging based on energy needs and optimizes utilization of generated renewable energy. Turbo Energy currently offers multiple models that cover most household installations.

All-in-One Sunbox

This product incorporates inverters, batteries and the rest of the components necessary to operate and protect the photovoltaic installation. This saves installation cost and assembly and configuration time while preventing errors. Notably, the latest Sunbox models also offer an EV charging option.

Software System

In communication with the inverter, the company’s software monitors energy flows between the photovoltaic panels, household consumption, storage and an optional electric vehicle charging station. The software allows users to customize an automatic backup mode based on weather forecasts, or manually select which part of the battery will be reserved for possible power outages. It also allows the battery to be used in a peak shaving mode, which leverages AI to trigger battery power when grid energy is most expensive, effectively reducing the amount of high-cost power drawn from the grid.

Market Opportunity

According to a report by Fortune Business Insights, a global research and reporting firm, the solar energy storage battery market was estimated to be worth $3.33 billion in 2022 and is projected to reach a value of more than $20 billion by 2030, marking a CAGR of 24.2% over the forecast period.

These batteries are crucial components of renewable energy systems, allowing for the storage of excess electricity generated by solar panels, so it can be used during times of no or low sunlight. By storing energy and supplying it when needed, these batteries reduce reliance on the power grid and maximize self-consumption while helping users avoid peak electricity rates. They also contribute to the transition toward a cleaner and more sustainable energy future by enabling residential consumers and businesses to use solar power even when the sun is not shining.

Management Team

Enrique Selva Bellvís is the CEO and founder of the Umbrella Group. In addition, he serves as vice-president of the Valencian Association of Energy Sector Companies industry group. Before his career in the solar energy sector, he was the founder and CEO of Innova Ingenieros Consultores. He holds a degree in industrial engineering with a specialization in energy from the Polytechnic University of Valencia and completed the Management Development Programme at the IESE Business School.

Mariano Soria is the Chief Innovation Officer for the Umbrella Group and serves as General Manager of Turbo Energy. He was CEO of Punt Moble XXI S.L. and continues to serve on that company’s board. Before that, he was the General Manager of REJMAR S.A., a land development company. He received his degree in industrial engineering and industrial organization from the Polytechnic University of Valencia, and his MBA from the European University of Madrid.

Alejandro Moragues is CFO of Turbo Energy. Previously, he held the position of Senior Corporate Auditor for U.S. company Euronet Worldwide Inc. and was an external auditor for PricewaterhouseCoopers. He holds a bachelor’s degree in business administration and management from the Polytechnic University of Valencia.

Manuel Cercos is Chief Commercial Officer at Turbo Energy. Previously, he held positions at Técnicas Aplicadas en Baterías S.L., where he served as Sales Director and Sales Manager. Before that, he worked as a Sales Technician at DAISA.

Turbo Energy S.A. (NASDAQ: TURB), closed Monday's trading session at $1.53, up 1.3984%, on 25,461 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $80.952/$.

Recent News

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF)

The QualityStocks Daily Newsletter would like to spotlight Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF).

Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF), a leading developer of rare earth element ("REE") processing technology, has entered a $4.28 million funding agreement with the government of Canada; the funding will be used to demonstrate the capabilities of Ucore Rare Metals' patent-pending RapidSX(TM) Rare Earth Element Separation technology. According to the agreement, the company will produce high-purity neodymium ("Nd"), praseodymium ("Pr") and praseodymium/neodymium compound ("NdPr") during a six-month period. The materials will be produced from 13–15 tonnes of Canadian and U.S. feedstock sources at Ucore's Ontario-based RapidSX Commercialization and Demonstration facility ("CDF") in Kingston, Ontario. The company noted that the budget for the product is 8.31 million, with $4.28 million provided through the government funding. "We would like to thank the government of Canada for this important funding," said Ucore Rare Metals chair and CEO Pat Ryan, PEng, in the press release. "China's recent announcements of increased scrutiny over the export of rare earth elements have raised concerns regarding the ongoing availability of these critical materials. The development of an alternative North American rare earth supply chain is more important than ever as the world moves toward the electrification of its vehicle fleet and other green initiatives."

To view the full press release, visit

A handful of Western critical-mineral explorers are looking to command premium prices for metals that will be key to the green-energy transition in exchange for ridding western countries of their reliance on China in the rare-earth metal segment. China is a key player in this sector and controls roughly 95% of the supply and production of all rare-earth metals, granting it a monopoly in an industry with significant strategic value. With tensions between China and western countries rising, and China using its monopoly to dictate prices as well as control export to stir conflict among end users, these countries are keen on reducing their reliance on China. Some Australian, Canadian and German critical-mineral explorers are willing to pay premium prices if it allows them to shift away from China and move the supply chain to market-determined prices. Companies such as Ionic Rare Earths in Australia and TSX-listed Aclara Resources are working on plans that could achieve this feat, company officials say. Sources familiar with the matter also reported that Neo Performance Materials from Canada and German miner Vacuumschmelze are discussing similar plans. Even without an assurance of premium prices, rare-metals companies such as Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) are already focused on producing these metals so that North American entities needing them can have a source close to home.

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) is a critical metals (“CM”) separation technology company executing an ESG-centered plan toward establishing a comprehensive North American critical metals supply chain. The company has developed a transformative commercial-ready technology, RapidSX™, for separating and purifying critical metals. Ucore intends to deploy this technology in pursuit of a CM supply chain independent of China for Western original equipment manufacturers (“OEMs”), most notably in the automotive and renewable energy industries.

Ucore’s vision is to become a leading advanced technology company providing best-in-class metal separation products and services to the mining and mineral extraction industry. Its initial focus is on processing heavy and light rare earth elements (“REEs”), disrupting a supply chain that is dominated by China.

China currently controls about 80% of the world’s access to REE mining projects and over 90% of the world’s REE processing capabilities, and it produces about 95% of the goods containing REE components.


Ucore is working to scale Western supply needs by establishing REE separation and rare earth oxide (“REO”) production capabilities in cooperation with strategic upstream supply and downstream offtake partnerships. The company, along with its industry partners, aims to unlock access to Western REEs for current consumer, energy, manufacturing and military sectors.

By 2025, Ucore expects to commercially separate U.S.-friendly sources of REEs and supply OEMs with REOs required to produce rare earth permanent magnets (“REPMs”) – the essential component of electric motors and generators required to support the world’s transition to electrification and sustainable energy sources.

The company intends to contribute to this initiative through the near-term development of a heavy and light rare-earth processing facility in Louisiana and subsequent development of Strategic Metals Complexes (SMCs) in Alaska and Canada, as well as through the longer-term development of its 100%-owned Heavy Rare Earth Element (HREE) mineral resource property at Bokan Mountain on Prince of Wales Island, Alaska.

Ucore is headquartered in Halifax, Nova Scotia.

Projects & Technology

RapidSX™ Demonstration Plant

The Kingston, Ontario, RapidSX™ Demonstration Plant commissioning process is underway. Once commissioned, the plant is designed to demonstrate the commercial capabilities of the RapidSX technology platform.

The RapidSX demo plant will show:

  • The techno-economic advantages of the RapidSX technology platform
  • The processing of tens of tons of heavy and light mixed rare earth element concentrates in a simulated production environment
  • The platform’s ability to operate for thousands of semi-continuous run-time hours
  • Production of high-purity NdPr, praseodymium, neodymium, terbium and dysprosium rare earth elements for early OEM product qualification trials

The demo plant is located within Ucore’s 5,000-square-foot RapidSX Commercialization and Demonstration Facility and is run by its laboratory partner, Kingston Process Metallurgy Inc. (“KPM”).

RapidSX™ Technology

Innovation Metals Corp., acquired by the company in 2020, developed the RapidSX separation technology platform with early-stage assistance from the United States Department of Defense, later resulting in the production of commercial-grade, separated rare earth elements at pilot scale.

RapidSX combines the time-proven chemistry of conventional solvent extraction (SX) with a new column-based platform that significantly reduces time to completion and plant footprint, as well as potentially lowering capital and operating costs. SX is the international REE industry’s standard commercial separation technology and is currently used by all REE producers worldwide for bulk commercial separation of both heavy and light REEs.

Utilizing similar chemistry to conventional SX, RapidSX is not a “new” technology, but it represents a significant improvement on the well-established, well-understood, proven conventional SX separation technology preferred by REE producers.

Strategic Metals Complex

Ucore, engineering partner Mech-Chem Associates Inc. and KPM are developing the full-scale engineering for the company’s first Strategic Metals Complex (SMC). The SMC is a planned REE separation and rare earth oxide production plant slated to commence construction in Louisiana in 2023. It is scheduled to initially process 2,000 tons of total rare earth oxides by the end of 2024, increasing to 5,000 tons in 2026.

The company has three initial U.S.-friendly feedstock agreements in place for the Louisiana complex, along with multiple developing offtake agreements. It received a C$16 million+ incentive package offer from Louisiana Economic Development to support construction of the SMC.

Bokan-Dotson Ridge REE Deposit

Ucore has invested over C$35 million to establish and validate the Bokan-Dotson Ridge resource in preparation for mine design and permitting. Initial drilling is complete, and a Preliminary Economic Assessment has been issued. Next steps for the project include a feasibility study, detailed mine design and permit acquisition. The project can be “near shovel ready” for construction in less than 30 months after receipt of the next stage of development funding.

Market Opportunity

According to a report by Grand View Research, the global rare earth elements market was valued at $2.8 billion in 2018 and is forecast to reach a value of $5.6 billion by 2025, achieving a CAGR of 10.4% during the period. Market growth is driven by increasing demand for these elements in the manufacturing of magnets and catalysts for the automotive industry. Rising demand for electric vehicles to reduce CO2 emissions is expected to propel the use of permanent magnets in the production of EV batteries.

China is the major producer and consumer of REEs. To maintain self-sufficiency and to meet future demand, China has been raising the export tariffs on rare earth elements shipped to various countries, including the U.S., Japan, India, Brazil and the European Union. This led to the current supply-demand gap in these countries, as they rely on imports from China.

China reduced the exports of REEs by 72% in the second half of 2010 to preserve its reserves of these elements and continues to export REEs at reduced levels, thereby affecting industries such as automotive, oil and gas, and electronics, which require an ample amount of rare earth elements.

Management Team

Pat Ryan, P.Eng., is Chairman and CEO of Ucore Rare Metals. He began as a director with the company when he developed a heightened interest in critical metals. Before joining Ucore, he founded and led a multimillion-dollar automotive OEM design and lean manufacturing company. His understanding of complex supply chains across international markets has led to a prime positioning as the global auto industry transitions to vehicle electrification. He holds a Bachelor of Engineering degree from Dalhousie University.

Peter Manuel is Vice President and CFO of Ucore. Prior to joining the company, he practiced as a Chartered Accountant for more than 17 years, providing consulting services to companies in a range of industries, with a focus on the financial services and resource sectors. He spent 10 years in England and Ireland providing assurance, strategic planning, corporate finance and other consulting services to a portfolio of both public and private entities. He holds a Bachelor of Commerce Degree from Dalhousie University.

Michael Schrider, MEng, P.E., is Vice President and COO of Ucore. He is a multidisciplinary engineer who has been involved in manufacturing, engineering and managing complex structural and mechanical systems projects since 1989. He was the Founder, President and Chief Engineer of Schrider & Associates and Alton Bay Design, both engineering services firms. He holds a bachelor’s degree in naval architecture and marine engineering from the University of New Orleans and a master’s degree in mining, geological and geophysical engineering from the University of Arizona.

Mark MacDonald is Vice President of Investor Relations at Ucore. He has over 25 years of experience implementing award winning business development and marketing programs at regional and national levels. As Vice President of Sales, he was responsible for Mediapro Communication’s growth as AT&T Canada’s leading B2B sales partner. He subsequently became Atlantic Regional Vice President of AT&T Canada Corp. He holds a Bachelor of Commerce degree from Dalhousie University.

Ucore Rare Metals Inc. (UURAF), closed Monday's trading session at $0.5026, up 2.5505%, on 38,432 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.395/$1.15.

Recent News


The QualityStocks Daily Newsletter would like to spotlight SOHM Inc. (OTC: SHMN).

A new study has found that individuals with inflammatory arthritis are plagued with psychological challenges that make it hard for them to maintain employment. The study, conducted by the Hospital for Special Surgery, was recently presented at the American College of Rheumatology Convergence 2023. One of the researchers involved in the study, Joan Westreich, stated that research had indicated that individuals suffering from inflammatory arthritis had a heightened risk for work disability, which could greatly impact their lives. Westreich also that within a decade of diagnosis, about 40% of those living with this condition wouldn't be able to work. While prior research on the condition had focused on addressing challenges in maintaining employment and barriers, this new study focused on the psychological experience of working while living with the challenges of this illness.  For their study, researchers used data collected by a clinical social work researcher who carried out interviews between March 2021–March 2022.  All interviews involved patients aged 18 years and older who were either employed at the time of the interview or had worked in the last five years. The interviews all averaged an hour and were carried out via Zoom. The treatments commercialized by companies such as SOHM Inc. (OTC: SHMN) targeting arthritis can help to relieve the physical symptoms as solutions are found for the mental-health side of this condition.

SOHM Inc. (OTC: SHMN) is a generic pharmaceutical manufacturing and marketing company with a vision of “Globalè Prospèro” (Global Prosperity). SOHM was founded in 1998 and is headquartered in Chino Hills, California.

The company’s primary goal is to create and produce cutting-edge generic medications that span a wide range of treatment areas, all while ensuring top-tier quality and keeping prices affordable. SOHM is dedicated to fully complying with all relevant regulatory prerequisites and upholding the most rigorous industry benchmarks, including the guidelines set forth by WHO-CGMP and USFDA.

Achievements and Milestones

SOHM is a recognized generic pharmaceutical manufacturer, with production and marketing of generic drugs covering all major treatment categories. SOHM also markets innovative formulations and packaging for various therapeutic segments, such as cosmeceuticals, nutraceuticals and OTC oral dosage formulations, with operations spanning India, the Philippines, Uganda, the U.S., the UK and the EU.

SOHM successfully launched a unique and innovative Salic-2 face wash, FōHM by SOHM, during the Oscar after party in Hollywood. The innovative Salic-2 offering in translucent gel form is marketed as an acne medication in the U.S. cosmeceutical market.

With proficiency in both manufacturing and marketing, SOHM stands out. The company holds licenses for producing over 300 products and has established distribution partnerships with firms in the United States, the Philippines and Uganda. Additionally, SOHM’s repertoire includes the launch of an innovative protein supplement, I-Prolec, featuring a distinct composition—a first-of-its-kind in India.

In 2012, SOHM gained recognition as “the most emerging company in the recent past” at the National Integrated Medical Association Conference. The company’s growth was underscored by its inclusion in the roster of ‘Fastest Growing Public Companies’ according to the Orange County Business Journal.

SOHM Today

SOHM brings all of its expertise and market knowledge toward a new vision. The company continues to develop, manufacture and market generic pharmaceutical drugs for various treatment categories. It offers its products in various dosage forms, including tablets and capsules, creams and topicals, ointments and liquids. The company also provides anti-arthritic/analgesics, dermatological drugs, gastrointestinal and respiratory drugs, biotechnology products, anesthetics, immunosuppressive agents and other various treatments. In addition, it offers a skincare line that includes dry dermatoses, mixed skin infection, acne vulgaris and seborrheic dermatitis products.

SOHM markets its products directly and through partner alliance agreements to drug wholesalers, mass merchandisers, chain drug stores and mail-order pharmacies primarily in the U.S. and has previously done business in the Far East, Africa and Southeast Asia. The company is working with its alliance partner in the African continent and Latin American countries.

SOHM has developed a comprehensive marketing strategy encompassing a diverse range of tactics to promote all products. SOHM uses the power of digital marketing channels, social media campaigns and targeted advertising to significantly enhance awareness and recognition of product offerings.

All distribution networks are strengthened through valuable partnerships. SOHM has gained access to the extensive U.S. market through a strategic alliance with different wholesalers catering to C-stores and retailers. The company has likewise partnered with a distribution firm that holds a remarkable network of more than 4,500 independent pharmacy accounts.

Additionally, a strong partnership with a prominent distribution network in New Jersey enables SOHM to facilitate nationwide distribution to big distribution houses, hospitals and retail chain stores which include but are not limited to Walmart, Publix, Sam’s and many more retail giants, thus extending the company’s market presence.

SOHM Long-Term

A report by Grand View Research estimated the global nutraceuticals market at $291.33 billion in 2022 and forecasts expansion at a compound annual growth rate (CAGR) of 9.4% from 2023 to 2030. The report states primary factors driving the market growth are preventive health care, increasing instances of lifestyle-related disorders, and rising consumer focus on health-promoting diets. Additionally, increasing consumer spending power in high-growth economies is projected to contribute to the growing demand for nutraceutical products.

Grand View valued the global NSAID market at $19.55 billion in 2021 and forecast it would expand to nearly $30 billion by 2030, marking a CAGR of 5.36% for the period. Projected growth is attributed to factors like the rising prevalence of chronic pain across the world, coupled with a growing global geriatric population. In addition, increasing demand for OTC NSAIDs and the rising adoption of NSAIDs in treating headaches, migraine, toothaches and menstrual pain is expected to boost market growth.

Fortune Business Insights estimated that the global cosmeceuticals market was worth $54.57 billion in 2022 and projects the market will grow to a value of $96.23 billion by 2029, marking a CAGR of 8.4% during the forecast period. The report credits the projected growth to the prevalence of skin disorders around the world and the inclination of dermatologists to prescribe or recommend these products as compared to other treatments.

SOHM envisions a future where it evolves into a prominent global corporation, expanding its reach across international borders while upholding its fundamental core values. The company aspires to extend its export portfolio to encompass 11 countries, showcasing a robust international presence.

Aiming for financial stability, SOHM is committed to maintaining sufficient working capital to support its growth endeavors. The company’s forward trajectory involves strategic collaborations, mergers with diverse brands and a focused approach to business expansion through vertical integration and a balanced mix of organic and inorganic strategies.

In this pursuit, SOHM is dedicated to establishing its proprietary network of partners within the over the counter (OTC) sector. Furthermore, the company seeks heightened recognition within crucial therapeutic domains, including oncology, HIV, cardiovascular health, diabetes care and skincare-dermatology, solidifying its prominent standing in these pivotal segments.

Management Team

Baron Night is CEO, President, and Director at SOHM Inc. He has over 40 years of experience in various industries with extensive contacts in emerging markets. His leadership and track record are great assets to the company as SOHM continues to strengthen its position and develop large-scale distribution of generic drug lines.

David Aguliar, Ph.D., is the COO of SOHM. He has 22 years of experience in the pharmaceutical industry, including multiple research positions and scientific publications. He has an extensive background in pharmaceutical Chemistry Manufacturing and Controls (CMC), as well as quality assurance experience in preclinical and Investigational New Drug (IND) application filings of allogeneic cell-based therapies. He has a deep understanding of regulatory and clinical pathways, coupled with an extensive scientific and technical background in the fields of pharmaceuticals, biopharmaceuticals and gene editing tools research.

Dr. Krishna Bhat, MD PHD, FACC, has a cardiology practice of over 35 years in the field of Clinical and Interventional Cardiology. He is a recipient of the 2021 Hall of Fame Award from the American Heart Association, which was awarded in recognition of his commitment to excellence in the field of Cardiovascular Care through his leadership as an outstanding physician, researcher, and educator. He is also a recipient of the Miles Canada Fellowship Award and the J. Louis Levesque Fellowship Award from Montreal Heart Institute in Montreal, Canada.

Dewey Rushing is a Senior Compliance Remediation and Quality Professional with over 30 years of experience in Quality Assurance and cGMP Compliance for products regulated by the U.S. Food and Drug Administration (FDA). He served as a trained Consumer Safety Investigator at the FDA and Instructor at the Los Angeles District. He has in-depth knowledge in technology transfer of biologics and pharmaceutical products, as well as validation of manufacturing equipment, facility cleaning and critical utility systems maintenance. He has an extensive background in auditing GMP facilities, implementing quality systems and performing gap assessments of manufacturing processes and facilities. He has also directed remediation projects in response to federal compliance audit observations.

Sowmya Jacob, MBA-PGP, possesses over a decade of accomplished and evolving expertise in human resources management, along with manufacturing and operations management. She earned an MBA, complemented by advanced marketing certifications. Demonstrating a track record of achievement, she excels in cultivating collaborative work environments and orchestrating transformative changes that lead to heightened productivity. With adeptness in business analysis, she has occupied senior managerial roles, showcasing her mastery. An engaged participant in professional circles, she maintains active memberships in SPHR and CHRP.

SOHM Inc. (OTC: SHMN), closed Monday's trading session at $0.0013, up 4%, on 7,538,778 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0005/$0.0015.

Recent News

Horizon Fintex | Upstream

The QualityStocks Daily Newsletter would like to spotlight Horizon Fintex | Upstream

Upstream, the revolutionary retail trading app for stocks and NFTs powered by Horizon Fintex and MERJ Exchange Limited, is spotlighted in a recent Medium blog comparing the new retail trading app with traditional trading apps. The blog is designed to explore the future of capital markets as the new platform challenges more traditional trading approaches and references Upstream's latest episode of its Twitter Space series, "Upstream Up Close." The series includes 10 to 15-minute conversations with key Upstream officials who discuss NFTs, blockchain, and trading on Upstream. The ninth episode put Upstream head-to-head against traditional trading apps. During this episode, Upstream head of marketing Vanessa and client success manager Amanda were joined by Anastasia and Fernanda, both digital marketing specialists. The group discussed the key differences between Upstream and other trading apps including the impact those distinctions could have on capital markets. Some of the challenges include it being cumbersome for retail investors outside the United States to purchase listed securities in the United States and Canada and the significant fees assessed by the exchanges that do allow it. In contrast, Upstream offers a user-friendly trading app that allows non-U.S. users to deposit and buy company shares directly and in a streamlined process. Because Upstream is a global trading app it provides direct access to the market, without requiring any intermediaries. Many platforms promote 0% trading fees, but this doesn't paint the full picture. "Another key differentiator is Upstream's public, on chain orderbooks, which offer transparency and real-time settlement, providing a fair and honest trading community," the blog noted. "Additionally, we enforce a no-short-selling policy through smart contracts, ensuring a level playing field for all participants. Upstream's smart-contract technology also allows for the acceptance of digital currency in the form of USDC stablecoin. This feature streamlines on/off ramps for both digital currency and USD holders. All Upstream USD accounts are also FDIC-insured up to $250,000. Additionally, our noncustodial approach works to give investors greater control over their assets. Unlike custodial platforms, Upstream users retain direct control of their securities and NFTs in their digital wallets/accounts, with transactions secured through biometrics." To view the full blog, visit

Horizon Fintex is a software business specializing in compliant securities solutions. The company aims to facilitate the future of capital markets by leveraging the regulatory experience of Wall Street bankers and the proven track record of technology veterans to bring focus to compliance, efficiency, security and transparency.

Horizon’s flagship product is the revolutionary trading app ‘Upstream’, a MERJ Exchange Market, and the first regulated market powered by a blockchain to offer both digital securities and NFT trading. Upstream traders experience T+0 settlement, best bids and offers displayed on a transparent public orderbook that prevents predatory market practices – all from a user-friendly trading app.


Horizon Fintex offers a full suite of end-to-end blockchain-enhanced software solutions to create a seamless experience for both issuers and investors. Its product suite includes:

  • Securitization & IssuanceETSware is an end-to-end Electronic Trading System streamlining capital raising from primary issuance through compliant secondary trading.
  • KYC Compliance OnboardingKYCware is a white label Know Your Customer (KYC) and Anti-Money Laundering (AML) compliance software solution offering best-in-class cryptographic security to compliantly onboard and verify user identity through a smartphone application.
  • AML Screening SoftwareAMLCop offers advanced Anti-Money Laundering (AML) software to streamline the verification of user details against a proprietary database of global sanctions, politically exposed persons (PEPs) and watchlists.
  • Cap. Table Management ToolsCustodyWare equips registered U.S. transfer agents with next-generation cap. table management software to manage securities on behalf of their clients pursuant to an SEC-registered or exempt securities offering.
  • Exchange & Trading App TechnologyOpen Order Book offers Ethereum blockchain securities exchange software to power the next generation of trading venues for digital assets.

Upstream – The Horizon-Powered Trading App

Upstream is a joint venture with MERJ Exchange (, an affiliate of the World Federation of Exchanges.

Upstream aims to be the premiere global trading hub offering issuers around the world exposure to a digital-first investor base that can trade using USDC digital currency along with credit, debit, PayPal, and USD (fiat) to increase liquidity and enhance price discovery; while also offering investors access to dual-listed companies, IPOs, crowdfunded companies, U.S. & Int’l. equities, digital coupons and NFTs directly from a user-friendly trading app.

Upstream aims to unlock liquidity for investors of all levels while offering industry-leading levels of transparency, accessibility and investor protections enforced using Ethereum blockchain technology.

Management Team

Brian Collins is the CEO of Horizon Fintex. He founded the company in 2010. From 1999-2010, Mr. Collins was CEO of Abbey Technology in Switzerland, specializing in the design of trading software for Swiss banks. Prior to this, he worked for Credit Suisse in Zürich, designing and building proprietary equity trading solutions. Mr. Collins graduated in 1990 with a BS in Computer Systems from the University of Limerick, Ireland.

Mark Elenowitz is the company’s President. He is a Wall Street veteran with over 29 years of experience. Mr. Elenowitz was the co-founder of a U.S. broker dealer and is Managing Director of two U.S. broker dealers, responsible for advising clients on compliance, capital structure and capital market navigation. He was responsible for leading the first successful Reg A+ IPO of a company to list on the NYSE and others which listed directly onto Nasdaq. He is a noted speaker at Small Cap and Reg A events, including the SEC Small Business Forum, and has been profiled in BusinessWeek and CNBC, as well as several other publications. Mr. Elenowitz is a graduate of the University of Maryland School of Business and Management with a BS in Finance and holds Series 24, 62, 63, 79, 82 and 99 licenses.

Dr. Andrew Le Gear is the CTO of Horizon Fintex. Prior to joining the company in 2013, he worked as a software engineer with Dell Inc. (2012-2013) and Lehman Brothers and Nomura Plc. (2007-2012). Dr. Le Gear was a co-founder of Juneberi Ltd., a research-driven software tech start-up (2004-2007). He graduated in 2006 with a Ph.D. in Computer Science from the University of Limerick, Ireland.

Peter Hall is the company’s CIO. Prior to joining Horizon Fintex in 2011, he worked at Microsoft (2008-2011), Atos Origin (2004-2008) and AIT Group Plc. (1998-2002). Mr. Hall has held CISSP certification since 2010. He graduated from the University of Sheffield, UK in 1995 and earned an MS from the University College London in 2006.

Mike Boswell is the CFO of Horizon Fintex. A Wall Street veteran, he co-founded a U.S. broker dealer and served as Chief Compliance Officer. Mr. Boswell was also Managing Director of TriPoint Capital Advisors, a merchant banking and financial consulting company, and CFO of Mission Solutions Group, a privately held defense sector firm. He earned an MBA from John Hopkins University and a BS in Mechanical Engineering from the University of Maryland. Mr. Boswell holds Series 24, 62, 63, 79, 82 and 99 licenses.

Recent News


PaxMedica Inc. (NASDAQ: PXMD)

The QualityStocks Daily Newsletter would like to spotlight PaxMedica Inc. (NASDAQ: PXMD).

Latest OTC Program Expands PharmcoRx Pharmacy's Ability to Provide Patients with Access to Additional Healthcare Benefits Covered by Medicare Advantage Plans

Progressive Care Inc. (OTCQB: RXMD) ("Progressive Care" or the "Company"), a personalized healthcare services and technology provider, today announced that its PharmcoRx ("PharmcoRx") pharmacies in Florida will expand their ability to provide customers with access to over-the-counter ("OTC") benefits through a new partnership with NationsBenefits LLC . ("NationsBenefits) for its NationsOTC program. NationsBenefits is a leading provider of supplemental benefits, flex cards, and member engagement solutions for health plans. OTC benefits are provided by many State and Nationwide Medicare Advantage ("MA") plans such as those offered by Humana, Devoted, Wellcare, and United Health. The OTC benefits provide MA members with the ability to purchase a wide array of goods including over-the-counter medicines, food, and groceries. The Centers for Medicare & Medicaid Services (CMS) estimates that in 2024, MA enrollment will rise from 31.6 million individuals in 2023 to 33.8 million, accounting for about 50% of all Medicare eligible. According to Statista, revenue in the OTC pharmaceuticals sector of the market will reach $39.3 billion in 2023 and is expected to grow annually by 3.53% (CAGR 2023-2028). Through the NationsBenefits partnership, PharmcoRx will be included in a list of NationsOTC participating pharmacies for program participants thereby providing patients with seamless access to valuable OTC benefits fully paid for by their MA plans along with their prescription medications when they are delivered to their homes free of charge.

PaxMedica Inc. (NASDAQ: PXMD) is a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic therapies (APTs) for the treatment of Autism Spectrum Disorder (ASD) and other serious conditions with intractable neurologic symptoms.

The company’s lead programs are focused on ASD, for which there are currently no approved pharmacologic treatments that target its cause and symptoms. Currently used treatments only address the symptoms of the condition, rather than targeting the pathophysiology itself.

PaxMedica is on a promising path to address these unmet medical needs, bringing hope to millions. Anti-purinergic therapies target the excess production of purines in cells. An overexpression of purines can offset homeostasis and result in an overproduction of cellular adenosine triphosphate, the main energy molecule in all living cells.

The company is headquartered in Tarrytown, New York.

Product Pipeline

PaxMedica is building a robust pipeline of products targeting ASD and related neurodevelopmental conditions. The company’s lead product in development may help eliminate, reduce or modulate some of the more troublesome aspects of ASD. That would open the potential for people with autism to integrate their behavior with others more successfully and improve their lives.

PaxMedica’s lead programs, PAX-101 and PAX-102, utilize the company’s proprietary source of suramin sodium, a broadly acting anti-purinergic therapy that has been known for over 100 years. Its current pipeline includes:

  • PAX-101 (IV Suramin) for ASD – PAX-101 completed a Phase 2B study for ASD in 2021. Suramin is a broadly acting APT and has reported positive results from a dose range study. The results of PaxMedica’s Phase 2B study, which targeted 52 subjects across six sites in South Africa, were presented to AACAP in October 2021.
  • PAX-102 (Intranasal Suramin) – PaxMedica has developed a proprietary intranasal formulation of suramin that is currently being evaluated in ASD and other neurodevelopmental conditions.
  • PAX-101 for HAT – Given suramin’s historical use as a treatment for Human African Trypanosomiasis (HAT), or African Sleeping Sickness, the company is also developing PAX-101 as a treatment for HAT. PaxMedica’s most advanced program is the pursuit of PAX-101 for early-stage East African HAT.
  • Selective APTs – PaxMedica has conducted several preclinical studies to evaluate other APTs that are more selective to specific purinergic receptors and may offer additional benefits over suramin.

Market Opportunity

According to a report by Fortune Business Insights, a leading global market research company, the global ASD therapeutics market was estimated at $1.93 billion in 2022 and is projected to grow from $2.01 billion in 2023 to $3.42 billion by 2030, a CAGR of 7.9% over the forecast period. As there is no current treatment for the core symptoms of autism, PaxMedica believes the addressable market for PAX-101, if approved, could greatly exceed these forecasts.

Autistic disorder, Asperger’s Syndrome and Pervasive Development Disorder are the three main types of ASD, affecting millions of people globally. A 2020 report by the U.S. Centers for Disease Control & Prevention estimated that one in 36 children in the U.S. have been diagnosed with autism disorder.

Several factors are expected to contribute to market growth prospects. A growing prevalence of the condition globally and rising awareness coupled with available treatment options are key factors expected to drive ASD therapeutics market growth during the forecast period. Growing investment in R&D to find effective treatments is also expected to fuel global market growth.

Management Team

Howard Weisman is Chairman and CEO of PaxMedica. He has been a founder and CEO of several specialty pharma and medical device companies. Most recently, he was executive chairman and co-founder of Sofregen, a biotech company. He also served as CEO and president of Seventh Sense Biosystems, a medical device development company. He also was founder, chairman and CEO of EKR Therapeutics, a specialty pharmaceutical company, and founder and COO of ESP Pharma, a company focused on cardio and neurovascular products. He has a bachelor’s degree in chemistry from Rutgers University.

David Hough, M.D., is Chief Medical Officer at PaxMedica. He is a neuroscience clinical development consultant who previously served as vice president at Janssen Research and Development and in various leadership roles over 17 years. Most recently, he was the compound development team leader for SPRAVATO® for treatment-resistant depression. Prior to that, he was the schizophrenia disease area leader. He played a pivotal role in the development programs for oral INVEGA®, INVEGA SUSTENNA® and XEPLION® for schizophrenia. He is a graduate of West Point and is board certified in psychiatry.

Stephen Sheldon is COO and CFO at PaxMedica. He has served as CEO of Thailand-based specialty healthcare company Indochina Healthcare Co. Ltd. since 2015. Previously, he was a consultant for PricewaterhouseCoopers Healthcare Advisory in the Chicago office. He was responsible for developing specialty pharmacy patient programs, strategy development for specialty products and compliance programs. He has an MBA from Thunderbird School of Global Management and a bachelor’s degree in computer science and visual arts from Bowdoin College.

PaxMedica Inc. (NASDAQ: PXMD), closed Monday's trading session at $3.9, up 1.8942%, on 7,337 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $2.00/$8.118.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

Lexaria, a global innovator in drug delivery platforms, has, since 2014, continuously worked on its patented DehydraTECH(TM) drug delivery technology

The technology has demonstrated overall effectiveness in enhanced delivery of fat-soluble molecules through the human gastrointestinal system, as affirmed by clinical testing

This overall effectiveness and push for its development has earned Lexaria 37 granted patents globally, with many patents pending

The company is constantly enhancing its patent portfolio, since granted patents can support an increase in licensing revenue

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is eyeing growth in license revenue from its intellectual property ("IP"). Since 2014, the company has continuously worked on its flagship technology – the patented DehydraTECH(TM) drug delivery technology – which has demonstrated the improvement of speed of onset, brain absorption, and bioavailability ( It is being investigated in association with dementia treatment, nicotine replacement, hypertension, and heart disease treatment, among other applications (

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has also collaborated with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has been granted patent protection for specific delivery of nicotine, vitamins, NSAIDs, antiviral drugs, cannabinoids and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Monday's trading session at $1.23, off by 6.0997%, on 48,383 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.6488/$3.5953.

Recent News

Progressive Care Inc. (OTCQB: RXMD)

The QualityStocks Daily Newsletter would like to spotlight Progressive Care Inc. (OTCQB: RXMD).

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the pricing of its public offering of an aggregate of 5,384,615 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 5,384,615 shares of common stock, at a combined public offering price of $1.30 per share (or common stock equivalent in lieu thereof) and accompanying warrant. According to the announcement, the warrants will be exercisable immediately upon issuance, at an exercise price of $1.30 per share, and will expire five years after the initial exercise date. Subject to the satisfaction of customary conditions, the closing is expected to occur on or about Nov. 22, 2023. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

To view the full press release, visit

Progressive Care Inc. (OTCQB: RXMD) is a health services organization based in Florida that offers personalized healthcare services and technology that supports the managed healthcare industry. Through its subsidiaries, Progressive Care provides Third-Party Administration (TPA), data management and analytics, COVID-19 diagnostics and vaccinations, 340B contracted pharmacy services, compounded medications, tele-pharmacy services, dispensing of anti-retroviral medications, medication therapy management (MTM), long-term care facility-targeted prescription medications, and health practice risk management.

The company collaborates with various healthcare organizations such as managed care organizations (MCOs), management services organizations (MSOs), accountable care organizations (ACOs), primary care providers, Medicare Advantage plans, Medicaid, commercial payors, pharmaceutical manufacturers, and distributors to enhance patient and provider engagement while improving the lives of patients with chronic diseases. Progressive Care offers a wide range of innovative solutions to address the dispensing, delivery, dosing, and reimbursement of clinically intensive, high-cost drugs.

Progressive Care currently operates four pharmacies in Florida, which generate the majority of its revenue. Pharmacy revenue is derived from dispensing medications, third-party administrative services to 340B-covered entities, and MTM services. The company also provides customized management, patient health risk reviews, and free same- and next-day delivery. Its focus is on complex chronic diseases that require multiyear or lifelong therapy, driving recurring revenue and sustainable growth. Progressive Care’s pharmacy revenue growth stems from its expanding breadth of services, new drugs coming to market, new indications for existing drugs, volume growth with current clients, and addition of new customers resulting from its emphasis on higher patient engagement, free delivery to the patient, and clinical expertise.

With licenses in 14 states, Progressive Care is poised for national expansion. The company anticipates revenue growth by signing new contract pharmacy service and data management contracts with 340B-covered entities, expanding data management and analytics services to healthcare organizations, and potential acquisitions.


Progressive Care’s wholly-owned subsidiaries provide services to client organizations and patients.

PharmcoRx Pharmacy

PharmcoRx, a full-service pharmacy, provides a complete healthcare ecosystem with services such as medication therapy management, rapid COVID-19 testing and vaccines, contactless medication delivery, Smart-Pack Unit Dosing packaging, custom compound medications, specialty medications, hospital transition pharmacy services, medication adherence monitoring, medication adherence risk management, and drug cost containment. PharmcoRx Pharmacy is a contracted pharmacy services provider for 340B-covered entities under the 340B Drug Discount Pricing Program.


ClearMetrX, a wholly-owned data management company, offers services that support healthcare organizations across the country. In September 2022, ClearMetrX launched the 340MetrX Platform, a software product developed by ClearMetrX that provides 340B-covered entities with data insights to effectively operate and maximize the benefits of the 340B program. 340MetrX supplies data access and delivers actionable insights that providers and support organizations can use to improve their practices and patient care. Its TPA services include management of wholesale accounts and contract pharmacies, patient eligibility with regard to the 340B drug program, development and review of 340B policies and procedures, and management of receivables.

Market Opportunity

According to an industry report by global consulting firm Berkeley Research Group, gross sales across the 340B drug program were valued at $116 billion in 2021 and are projected to grow to $280 billion by 2026, achieving a CAGR of more than 19% over the period.

The 340B drug pricing program allows eligible healthcare clinics and hospitals (the covered entities) to purchase outpatient drugs at a 20-50 percent discount to treat low-income, uninsured, or underinsured populations. The program’s forecast growth is expected to benefit Progressive care’s business of providing 340B program services to covered entities through the nationwide expansion of ClearMetrX, its third-party administration and data-management business.

Management Team

Charles M. Fernandez is CEO and Chairman of the Board of Directors of Progressive Care. Mr. Fernandez is also the Executive Chairman and CEO of NextPlat Corp. (NASDAQ: NXPL) and has over 30 years of experience in identifying profitable start-up and dislocation opportunities, building significant value and executing exit strategies as an entrepreneur and global investor. In 2008, he joined Fairholme Capital Management. As president, he co-managed all three Fairholme funds and was commended for bringing in a $2 billion gain for shareholders. Throughout his impressive career in media, pharmaceuticals, healthcare, finance and technology, Mr. Fernandez has participated in more than 100 significant mergers, acquisitions and product development projects. He was the founder, chairman and CEO of eApeiron Solutions LLC, a brand protection and e-commerce company in partnership with Alibaba (NYSE: BABA) and Eastman Kodak (NYSE: KODK) which was successfully sold to Smartrac, a leading developer, manufacturer and supplier of RFID and Internet of Things (“IoT”) solutions and a unit of Avery Dennison Corporation (NYSE: AVY).

Other top management team members include Chief Operating Officer Birute Norkute, Chief Financial Officer Cecile Munnik, and Pamela Roberts, who serves as the company’s Pharmacist in Charge.

FingerMotion Inc. (RXMD), closed Monday's trading session at $0.98, off by 44%, on 4,368,851 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.95/$69.19.

Recent News

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI)

The QualityStocks Daily Newsletter would like to spotlight Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI).

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology ("I&I") biological products primarily for the treatment of autoimmune and infectious diseases, and providing end-to-end boutique CDMO services, has regained compliance with NASDAQ listing rules regarding minimum stockholders' equity. The company received formal notification of the status from NASDAQ. According to the announcement, NASDAQ indicated that the exchange had determined that SCNI complies with listing rule 5550(b)(1), which requires listed companies to maintain a minimum $2.5 million in stockholders' equity, based on the content of the company's Form 6-K. The company intends to continue to comply with the listing rule based on a revised financial facility contract with the European Investment Bank ("EIB") extending the maturity of the EIB's loan from 2027 to 2031; a recent change of the company's functional currency from NIS to USD to better reflect the company's new business strategy; and an updated assessment by an external appraisal of Scinai's weighted average cost of capital ("WACC") to 35%; the company anticipates that this new WACC will be incorporated in its financial statements for the year ending Dec. 31, 2023. The company noted that it has received a letter regarding noncompliance with an additional NASDAQ listing requirement to maintain a minimum bid price of $1 per share. The letter is only a notification of deficiency and has no immediate effect on the listing or trading of the company's American Depository Shares ("ADSs").

To view the full press release, visit

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases.

In collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, Scinai is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma and psoriasis.

NanoAbs, also known as VHH-antibodies or Nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration and efficient production. Scinai is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.

The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK and Bristol-Myers Squibb.

Since its founding, Scinai has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and it built, owns and operates a 20,000 sq. ft. state-of-the-art GMP biologics manufacturing facility housing its laboratories, production facilities and offices.

Lead Candidate: Inhaled COVID-19 NanoAb

In December 2021, Scinai signed definitive agreements with the Max Planck Society – parent organization of the Max Planck Institute for Multidisciplinary Sciences– and the UMG to enter a strategic collaboration for the development and commercialization of innovative COVID-19 NanoAbs.

The company is planning a rapid development path that leverages its expertise and capabilities in biological drug development and manufacturing. Scinai anticipates preclinical proof-of-concept results for an inhaled COVID-19 NanoAb by the end of 2022, with initial Phase 1/2a human clinical trial results expected in 2023.

The intended inhaled mechanism of delivery of Scinai’s COVID-19 NanoAb formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected. Inhaled delivery has shown to be cheaper, more convenient and likely safer for patients and providers.

NanoAb Pipeline: Psoriasis, Asthma and More

The COVID-19 NanoAb development agreement is part of a broader five-year research collaboration agreement signed in March 2022 covering discovery, development and commercialization of NanoAbs for several other disease indications with large market medical needs, including asthma, psoriasis, macular degeneration and psoriatic arthritis.

Scinai has an exclusive worldwide license for development and commercialization of COVID-19 NanoAbs and exclusive options for similar worldwide licenses for NanoAbs for the above mentioned additional large market disorders currently underserved by approved therapeutic antibodies.

Academic research teams from MPG and UMG have verified strong affinity by the new NanoAbs to their biological target molecules and high thermostability. They have also demonstrated strong neutralization by several NanoAb candidates of their respective target molecules. Neutralization studies of the other NanoAbs are expected to begin later in 2022.

Based on the promising results, Scinai will focus development efforts beginning with the following NanoAbs:

  • NanoAbs targeting IL-17 as drug candidates for the potential treatment of psoriasis and psoriatic arthritis
  • NanoAbs targeting IL-13 and NanoAbs targeting TSLP as drug candidates for the potential treatment of asthma

These are conditions for which the antibody target is validated by existing treatments and the mechanism of action is well understood. Both represent large medical needs and growing markets. Scinai anticipates preclinical proof-of-concept for at least one of these NanoAbs in 2023. This is in addition to the aforementioned human clinical Phase 1/2a for the inhaled COVID-19 NanoAb therapy, which is also anticipated in 2023.

CDMO Services

While NanoAb pipeline development is Scinai’s core focus, the company also offers its cGMP manufacturing facility, aseptic fill and finish suite, laboratories and experienced professionals for contract development and manufacturing organization (CDMO) services. This offering is designed to keep the Scinai team abreast of the latest industry developments and trends while building experience and generating revenue to support the company’s NanoAb pipeline development.

Market Opportunity

COVID-19 treatment, target of the company’s lead NanoAb therapy candidate, had an estimated market size of $22 billion in 2021.

Future Scinai drug candidates will target conditions with large markets growing at attractive CAGRs.

The global asthma treatment market was valued at $18.08 billion in 2019 and is projected to reach $26.01 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period, according to Fortune Business Insights. The research firm predicts that the global psoriasis treatment market will grow from $26.37 billion in 2022 to $47.24 billion by 2029, exhibiting a CAGR of 8.7% over the forecast period.

Management Team

Amir Reichman is Scinai’s CEO. He previously was Head of Global Vaccines Engineering Core Technologies at GSK Vaccines in Belgium. Prior to that, he held leadership roles at Novartis Vaccines’ Global Vaccines Supply Chain Management organization. He was the first employee of NeuroDerm Ltd., a company focused on transdermal drug delivery, and served as Senior Scientist until his departure in 2009. He earned a M.Sc. in Biotechnology Engineering from Ben-Gurion University and an MBA in Finance and Health Care Management from the University of Pennsylvania’s Wharton School.

Tamar Ben-Yedidia, Ph.D., is Chief Science Officer at Scinai. She has more than 30 years of experience in immunology, with specific expertise in the development of vaccines. She began her career with Biotechnology General Ltd., working on development of a recombinant Hepatitis-B vaccine. She later joined the Weizmann Institute of Science, working on the design of a peptide-based vaccine against several pathogens. She is widely published, with numerous refereed articles and invited reviews in various scientific journals. She received her Ph.D. from the Weizmann Institute.

Elad Mark is COO at Scinai. He has over 15 years of biotechnology industry experience encompassing diverse project stages including feasibility studies, conceptual and detailed design, commissioning, qualification and process validation. Prior to joining Scinai, he led Novartis’s $800 million investment in a biologics facility in Singapore. With Biopharmax and Antero, both global pharmaceutical engineering companies, he successfully led projects in Israel, China and Singapore. He holds a BSc. in Engineering from the Afeka Tel Aviv Academic College of Engineering and an MBA from the Open University of Israel.

Uri Ben-Or is CFO at Scinai. He has served as CFO with public life science companies traded on the TASE, OTC and Nasdaq. Ben-Or provides his services to Scinai through CFO Direct, a company he founded and for which he serves as CEO. He served as the VP of Finance of Glycominds, a leading biotechnology company, and as CFO of a spin-off from Telrad Networks. He also served as a Corporate Controller at Menorah Capital Markets and as an Auditor at PWC. He holds a B.A. in Business from the College of Administration, an MBA from Bar-Ilan University, and is a CPA.

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), closed Monday's trading session at $0.59, off by 6.3492%, on 12,195 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.58/$11.49.

Recent News

SuperCom Ltd. (NASDAQ: SPCB)

The QualityStocks Daily Newsletter would like to spotlight SuperCom Ltd. (NASDAQ: SPCB) .

SuperCom, a global leading provider of traditional and digital identity solutions, just announced its latest order from the Romanian government to the tune of $3.4 million

SuperCom will help Romania's Ministry of Interior to bolster its EM project, based on its PureSecurity Suite, covering domestic violence monitoring, GPS tracking of offenders, as well as home detection monitoring

Deliveries are set to be met by the end of Q4 2023, and SuperCom's management is optimistic that the order will boost the company's overall value proposition and lead to many more orders down the line

SuperCom (NASDAQ: SPCB), a leading global provider of traditional and digital identity solutions offering advanced safety, identification, and security products and solutions to governments, recently announced its continued collaboration with the Romanian government. The latest order from the country's Ministry of Interior is part of an ongoing $30 million project, bolstering the country's National Electronic Monitoring ("EM") Project (

SuperCom Ltd. (NASDAQ: SPCB) provides secured solutions for the e-government, IoT and cybersecurity sectors. Since 1988, the company has been a trusted global provider of traditional and digital identity offerings, providing cutting-edge electronic and digital security solutions to governments and organizations, both private and public, around the world.

SuperCom’s mission is to revolutionize the public safety sector worldwide through proprietary electronic monitoring technology, data intelligence, and complementary services.

The company is headquartered in Tel Aviv, Israel, with offices in California and other regions in the U.S.

Business Units

IoT and Connectivity

SuperCom IoT products and solutions provide advanced electronic monitoring solutions and services to criminal justice agencies, enabling customers to detect unauthorized movement of people, vehicles, and other monitored objects. The company provides an all-in-one, field-proven PureSecurity offender monitoring suite, accompanied by services such as GPS monitoring, home detention, domestic violence prevention, and more. The company’s services are specifically tailored to meet each client’s needs.

SuperCom’s proprietary Puresecurity suite of hardware, connectivity, and software components is the foundation for its criminal justice services and offerings. SuperCom is leveraging its extensive technology expertise to implement groundbreaking artificial intelligence (AI) technologies into various parts of its core offerings. By leveraging the power of AI, SuperCom’s PureSecurity platform can offer new abilities, such as amplified data analysis, predictive modeling, and streamlined automation – all geared toward optimizing decision-making and operational efficiency.

Competitive advantages of SuperCom’s technology include:

  • Long Battery Life (No Tag Charging Required)
  • Ultra Lightweight Form Factor
  • Next-Gen Location Tech
  • Protection of Domestic Violence Victims
  • And More



In 2015, SuperCom identified the cybersecurity market as a fast-growing space with significant advantages due to synergistic technologies and a shared customer base with its e-Gov and IoT business units. Consequently, SuperCom strategically acquired Prevision Ltd., a company with a strong presence in the market and a broad range of competitive cybersecurity services.

During the first quarter of 2016, SuperCom acquired Safend Ltd., an international provider of cutting-edge endpoint data protection guarding against corporate data loss and theft through content discovery and inspection, encryption methodologies, and comprehensive device and port control.

Both acquisitions significantly expanded the breadth of the company’s global cybersecurity capabilities.


Through proprietary e-government platforms and innovative solutions for traditional and biometrics enrollment, personalization, issuance, and border control services, SuperCom has helped governments, and national agencies design and issue secured multi-identification, or Multi-ID, documents and robust digital identity solutions to their citizens, visitors, and lands.

The company has focused on expanding its activities in the traditional identification, or ID, and electronic identification, or e-Gov, markets, including the design, development, and marketing of identification technologies and solutions to governments in Europe, Asia, America, and Africa using SuperCom’s e-Government platforms.

Market Opportunity

Data from Berg Insight estimates the market for electronic monitoring solutions will grow from $1.2 billion in 2021 to $2.1 billion in 2026, marking a CAGR of 10.8% for the forecast period.

High recidivism rates, prison overcrowding, and soaring incarceration costs are some factors that are driving the electronic monitoring of offenders’ market growth.

An analysis by ReportLinker forecasts that the global cybersecurity market will grow from an estimated value of $173.5 billion in 2022 to $266.2 billion by 2027, achieving a CAGR of 8.9% for the period.

The increased number of data breaches worldwide, the ability of malicious actors to operate from anywhere in the world, the links between cyberspace and physical systems, and the difficulty of reducing vulnerabilities and consequences in complex cyber networks are some factors driving the cybersecurity market growth.

Management Team

Ordan Trabelsi is President and CEO of SuperCom. He has over 15 years of experience as CEO, growing high-tech companies globally. He also has experience in research and development and product innovation, as well as hands-on experience in cybersecurity, encryption, advanced mathematics, and mobile and internet network technologies. Prior to joining SuperCom, he served as co-founder and CEO of Klikot Inc., a global social networking company. He holds an MBA from Columbia University and a B.Sc. in Computer Engineering from The Technion: Israel Institute of Technology.

Barak Trabelsi is COO of SuperCom. He has expertise in big data, cyber, mobile, and internet network technologies, as well as extensive experience in product development and strategies. Prior to joining SuperCom, he served as Senior Product Manager at Equinox Ltd. Before that, he served for four years as VP of R&D at Sigma Wave, a wireless, security, and internet-focused company. He holds a B.Sc. in Computer Science and Business, as well as an MBA from Tel Aviv University.

Gil Alfi is VP of Sales at Safend Ltd., SuperCom’s cybersecurity subsidiary. He joined SuperCom in 2016 as VP of Business Development for Safend. He has more than 18 years of experience in technology companies. He served as an R&D team technology lead for more than seven years and as Director of Product Management for various telecom and wireless companies for more than 10 years. Prior to joining SuperCom, he served as Regional Sales Director at Safend, managing sales regions in Europe and Africa. He holds a B.Sc. in Computer Science and Mathematics and an M.Sc. in Computer Science from Bar-Ilan University.

SuperCom Ltd. (NASDAQ: SPCB), closed Monday's trading session at $0.3735, off by 0.823155%, on 460,388 volume. The average volume for the last 3 months is 5.215M and the stock's 52-week low/high is $0.3416/$2.695.

Recent News

Utopia VR

The QualityStocks Daily Newsletter would like to spotlight Utopia VR

Utopia VR is one of the world’s first ‘Metaverse-As-A-Service’ solutions for business. The company’s hosted and managed subscription software provides businesses a low barrier to entry, browser-based, device agnostic platform where they can manage their own private 3D metaverse meeting spaces. Users can host and attend Zoom-like virtual meetings in lifelike virtual reality – with no software downloads – engaging their audiences in a more collaborative and fun way.

Utopia VR has many technology and privacy advantages over solutions built on other metaverse marketplaces such as Horizon Worlds (META) or Decentraland. Utopia VR works on all devices – PC, mobile and virtual reality headsets – whereas many competitors only work in VR or on PC.

Utopia VR is headquartered in Kelowna, B.C.


Utopia VR’s The Metaverse for Everyone™ is a one-click, web-based, avatar-driven, mobile-friendly audio- and video-conferencing platform that utilizes innovative 3D web technology. Utopia VR’s virtual platform works on digital devices including PCs, mobile phones and VR headsets such as Oculus Quest or HTC Vive. No software or proprietary hardware is needed.

Users navigate through the various VRoom environments by using avatars. Users can walk, talk and sit – just like they do in the real world. A user’s avatar can be controlled with a computer keyboard, smartphone or virtual reality headsets. Text chat, voice and video is ever-present and used to communicate with others in the VRoom. For important meetings and presentations, users can also import audio, video, 2D art and images, animated 3D objects, PDF files and their favorite NFTs by simply dragging and dropping files into a VRoom or pasting a video link from supported media platforms.

Organizations that have an existing website can transition their digital assets, including text, images, video, PDFs, slideshows and more, to VRoom environments with a simple copy and paste. This will allow their customers and audiences to experience their brand in a whole new, immersive environment.
Utopia VR’s mobile app enables users to personalize their own 3D environments and then schedule business meetings or social meetups in seconds through a proprietary link management system. The app is available for iPhone and iPad users. The company’s website mirrors the app, which means users can access Utopia VR directly from a PC, laptop, tablet, or VR headset without downloading the app.

Market Outlook

Regarded as the next iteration of the internet, the metaverse is a virtual space where the physical and digital worlds coexist and interact, encompassing virtual reality, augmented reality, extended reality and mixed reality, as well as making use of artificial intelligence and other technologies.

Data consolidator Statista estimated that the global metaverse market size stood at $38.85 billion in 2021 and projected the market would grow to be worth $47.48 billion in 2022. From there, Statista forecasts the value of the metaverse market will explode to reach $678.8 billion by 2030, achieving a CAGR of more than 39% over the period.

The metaverse could create $5 trillion in opportunity by 2030, according to McKinsey & Company.

Management Team

Stuart Gray, President, Co-Founder and director of Utopia VR, has been an officer and director for both private and publicly traded companies and has led public offerings for junior listed companies that have gone on to realize multibillion-dollar market valuations. He previously was a consultant and quarterbacked taking eXp World Holdings Inc. (NASDAQ: EXPI) public. eXp is a disruptive, no bricks and mortar, real estate brokerage firm with 85,000 agents worldwide using its virtual, software-based, metaverse platform for closing transactions, training and events.

Cory Braden, CTO and director of Utopia VR, is a forward-thinking strategic leader with over 20 years of experience in delivering software as a service. Recognized for a positive leadership style and excellent communication skills, he is well-versed in user experience, complex application architectures, cloud infrastructure and management of high-performance teams.

Terry Woloszyn, VP of Sales and Advisory at Utopia VR, brings vast technical and sales experience to the company. Before joining Utopia VR, he conceived and launched a data security startup and graduated from two startup accelerator programs. He has personally raised $20 million in equity venture funding.

Recent News


OK Stone Engineering Inc.

The QualityStocks Daily Newsletter would like to spotlight OK Stone Engineering Inc.

OK Stone Engineering Inc. is a Texas-based company formed to manufacture engineered quartz slabs to be used as materials for countertops and tile in the building and construction industry. The company’s manufacturing process uses next-generation technologies which reduce costs, improve the quality of the finished product and increase safety of workers in the manufacturing process.

OK Stone is the first high tech source of U.S.-made quartz stone products. The company, with joint venture partner Breton S.p.A., has announced a new factory for engineered stone in Fort Worth, Texas, to fill the massive supply gap in the U.S. market, where the domestic shortage is projected to increase to 140 million square feet annually by 2026. Construction of the facility is scheduled to begin in 2024, with production projected to start in mid to late 2025 and the is facility projected to be scaling to full production in early 2026.

The factory will be the first in the U.S. to employ Breton’s Bioquartz® technology, a transformative state-of-the-art manufacturing process. There are only nine engineered stone slab manufacturers in the U.S., and seven of those are based on older Breton technology. Only OK Stone is investing in this latest technology while other manufacturing facilities risk falling behind.


OK Stone’s licensed Bioquartz® manufacturing technology, which has been under development for a decade, will provide a significant competitive advantage in the market by solving the most frustrating problems faced by customers. Breton, based in Italy, is the definitive international leader in designing and developing engineered stone production plants, with more than 95% of global market share.

This next-gen manufacturing technology will allow OK Stone to source a more reliable and less expensive supply of domestic raw materials, replacing variable supplies from Asia. It also reduces costs by more than 10% while producing quartz slabs with an unlimited range of aesthetic effects that older manufacturing technologies cannot replicate.

Importantly, the Bioquartz® process eliminates the risk that workers can develop silicosis, an incurable lung disease caused by inhaling crystalline silica particles. Expected new government regulations to prevent silicosis are likely to impact other U.S. manufacturers. The company’s expected regulatory compliance, as well as its avoidance of international shipping costs for raw materials – which have been unstable since 2021 – are among the factors likely to provide OK Stone with major competitive advantages in the market.

The company will sell its factory output through the existing network of stone distributors that supply the building and construction industry.

Market Opportunity

According to a report by Allied Market Research, a research, consulting and advisory firm, the global engineered stone market was valued at $21.1 billion in 2021 and is projected to reach $35.1 billion by 2031, growing at a CAGR of greater than 5% for the forecast period.

Engineered stone is used in a number of applications in the construction industry, including countertops, flooring and wall tiles, fireplaces and more. The report states that rapid expansion in construction is boosting the global demand for engineered stone.

Management Team

OK Stone’s management team recently designed, built and operated a Breton factory with more than $100 million in annual revenues.

The CEO of OK Stone has almost two decades of experience in the engineered stone industry. He began as a production engineer, later hired as a factory manager and eventually in the role of Managing Partner an an Industrial Investment fund, focusing on investments in engineered stone. He holds a Mechanical Engineering degree and an MBA.

The Chief Marketing Officer at OK Stone has more than 15 years of experience as a sales and marketing executive in the industry. He has worked for the top tier of engineered surfaces companies as well as a significant U.S.-based engineered stone company. He has recently been Sales and Marketing Director of a fully scaled Breton equipped factory, and was previously part of the founding team at a separate Breton factory, where he worked extensively in the U.S. market.

Ronald Max is COO at OK Stone. He has more than 35 years of experience in operations and finance. He has been involved in over $4 billion in real estate transactions and has extensive expertise in complicated ownership structures such as sale-leaseback financing, ground lease bifurcations and real estate securities offerings. In addition, he has experience in creating operating budgets, financial management and industrial real estate development for highly scaled enterprises.

Recent News


The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.